Abstract 1069P
Background
Grade 3/4 immune-related adverse events (severe irAEs), caused by anti-PD-1/PD-L1 antibodies, can lead to fulminant and even fatal consequences. However, the identification of biomarkers for irAEs prediction is lacking. Previous studies have suggested that germline mutations and T-cell receptor (TCR) diversity are associated with the development of irAEs during cancer immunotherapy. Here, our study aims to explore promising biomarkers for predicting severe irAEs.
Methods
Patients who received immune checkpoint inhibitors (ICIs) treatment between November 2021 and December 2022 were enrolled in a study with follow-up. Blood samples were collected at baseline and from those with severe irAEs during or after treatment. Blood samples underwent whole exome sequencing and TCR sequencing. Germline mutations were compared between severe irAEs and non-severe irAEs groups, with additional TCR analysis including diversity index and cluster analysis.
Results
The study enrolled 128 patients, among whom 12 (9.38%) developed serious irAEs. Germline mutations in 10 immune-related genes (MMEL1, MDM4, GPR35, LPP, BACH2, EGFR, JAK2, PTEN, SMAD3, TYK2) were significantly different between severe and non-severe irAEs groups (p < 0.05). TCR sequencing analysis revealed that 3 motifs in the severe irAEs group and 7 motifs in the non-severe irAEs group were also significantly different (p < 0.05). A PLS-DA analysis combining biomarkers, genes, and motifs successfully distinguished between the two groups. Additionally, we observed a significant decline in CDR3 counts from baseline to post-severe irAEs in TCR.
Conclusions
Study results indicated that germline mutations and changes in TCR characteristics may predict severe irAEs in cancer immunotherapy, emphasizing the need for further research and personalized management of these adverse events.
Clinical trial identification
ChiCTR2100052367.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Haplox Biotechnology Co., Ltd.
Disclosure
S. Cheng: Financial Interests, Personal, Full or part-time Employment: Haplox Biotechnology Co., Ltd. Z. Yang: Financial Interests, Personal, Full or part-time Employment: Haplox Biotechnology Co., Ltd. S. Chen: Financial Interests, Personal, Member of Board of Directors: Haplox Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19
1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Presenter: Hsiu-Tzu Wang
Session: Poster session 19
1059P - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent clinical outcomes and immune responses of clear cell renal cell carcinoma
Presenter: Dingwei Ye
Session: Poster session 19
1061P - Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Presenter: María Del Mar Noblejas Lopez
Session: Poster session 19
1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Presenter: Christophe Tournigand
Session: Poster session 19
1063P - Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Presenter: Caterina Tozzi
Session: Poster session 19
1065P - Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Presenter: Federica Pecci
Session: Poster session 19
1066P - Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Presenter: Víctor Albarrán
Session: Poster session 19
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19